

Begoña Mellado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6758983/publications.pdf>

Version: 2024-02-01

42
papers

4,102
citations

331259

21
h-index

264894

42
g-index

44
all docs

44
docs citations

44
times ranked

5942
citing authors

#	ARTICLE	IF	CITATIONS
1	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 338-348.	13.9	885
2	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	6.3	778
3	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 1473-1482.	5.1	762
4	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. <i>Lancet Oncology</i> , The, 2011, 12, 1143-1150.	5.1	217
5	Interleukin 6, a Nuclear Factor- κ B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor- κ B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity. <i>Clinical Cancer Research</i> , 2006, 12, 5578-5586.	3.2	147
6	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1270-1284.	1.9	131
7	Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 665-675.	1.9	98
8	KIT Expression in Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 676-678.	2.1	95
9	Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 329-339.	1.9	92
10	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e86263.	1.1	76
11	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	3.4	75
12	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 248-258.	5.1	73
13	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	0.9	64
14	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 709-713.	0.9	63
15	C-KIT EXPRESSION IN SARCOMATOID RENAL CELL CARCINOMA: POTENTIAL THERAPY WITH IMATINIB. <i>Journal of Urology</i> , 2004, 171, 2176-2180.	0.2	59
16	Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon. <i>Journal of Clinical Oncology</i> , 2002, 20, 4032-4039.	0.8	53
17	Nuclear factor- κ B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. <i>Prostate</i> , 2013, 73, 512-521.	1.2	52
18	Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. <i>Clinical and Translational Oncology</i> , 2009, 11, 5-10.	1.2	49

#	ARTICLE	IF	CITATIONS
19	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA); Tj ETQq1 1 0.784314 rgBT /Overlook 2017, 18, 672-681a.	5.1	49
20	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , 1998, 17, 761-767.	2.6	31
21	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	1.3	29
22	Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 10604-10616.	0.8	21
23	Molecular biology of renal cell carcinoma. <i>Clinical and Translational Oncology</i> , 2006, 8, 706-710.	1.2	18
24	Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 265-270.	0.9	18
25	Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon- γ in patients with metastatic melanoma. <i>Melanoma Research</i> , 2006, 16, 59-64.	0.6	17
26	Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 308-318.	2.0	17
27	Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 127-136.	2.0	17
28	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. <i>European Urology</i> , 2021, 79, 722-733.	0.9	17
29	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	1.8	15
30	Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 59165-59180.	0.8	15
31	The influence of treatment sequence in the prognostic value of <i>TMPRSS2-ERG</i> as biomarker of taxane resistance in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 1970-1981.	2.3	13
32	Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 452-460.	0.9	11
33	Expression and mutational analyses of KIT and PDGFR α in sarcomatoid renal cell carcinoma. <i>Histopathology</i> , 2009, 55, 230-232.	1.6	9
34	Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. <i>BMC Cancer</i> , 2016, 16, 135.	1.1	7
35	Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 594023.	1.3	7
36	Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial. <i>Clinical and Translational Oncology</i> , 2005, 7, 250-254.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	1.3	4
38	Radium-223 international early access program: results from the Spanish subset. <i>Future Oncology</i> , 2018, 14, 41-50.	1.1	3
39	Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets. <i>Archivos Espanoles De Urologia</i> , 2013, 66, 453-62.	0.1	3
40	Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma. <i>Cancers</i> , 2021, 13, 6235.	1.7	2
41	c-kit Overexpression in Chromophobe Renal Cell Carcinoma Is Not Associated With c-kit Mutation of Exons 9 and 11. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1544-1545.	2.1	1
42	Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. <i>Medical Oncology</i> , 2019, 36, 29.	1.2	0